Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraputamenal CDNF in Parkinson's Disease
NCT03295786Phase 2Completed
- Sponsor
- Herantis Pharma
- Start
- Sep 2017
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of cerebral dopamine neurotrophic factor in Parkinson's disease (PD) (3 arms), sponsored by Herantis Pharma. Primary endpoints: Adverse events (AEs), Electrocardiogram and 6 more. Started Sep 2017; status: completed.
02
Drugs
cerebral dopamine neurotrophic factor
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03295786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03295786.